TalkMed's (SGX:5G3) attributable profit to owners jumped 90% during the second half of 2024 to SG$34.0 million from SG$17.9 million a year earlier, according to a filing with the Singapore Exchange on Tuesday.
Earnings per share rose to SG$0.0254 compared with SG$0.0134 in the comparable period.
Revenue declined 2% year over year to SG$45.1 million from SG$46.0 million, due to a decrease in revenue from the oncology services segment.